Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone
- PMID: 16033090
Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone
Abstract
Aims: (a) To assess the expression patterns of HER2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive ductal cancer (IDC) and IDC associated with carcinoma in situ (IDC/DCIS) and (b) to determine if there is a differential expression of these molecular markers between IDC and IDC/DCIS.
Materials and methods: Paraffin-fixed breast cancer samples, diagnosed with only one histological invasive tumor (IDC (n=130), and IDC/DCIS (n=36) were analyzed by immunohistochemical means. The non-parametric Mann-Whitney and chi2 tests were used to evaluate any statistical differences between different groups. Significance was assumed at p<0.05.
Results: A significant increase of the tumor grading was observed between IDC and IDC/DCIS (p<0.05). Her2/neu amplification was demonstrated in 49.6% of IDC compared to 31% of IDC/DCIS (p<0.05). ER expression showed no statistical differences between IDC and IDC/DCIS. The PR expression was demonstrated in 71% of IDC with significantly lower intensity than IDC/DCIS (p<0.05). The Ki67 expression was significantly higher (p<0.05) in IDC cases (64%) versus IDC/DCIS (49.7%). No differences were observed between IDC and IDC/DCIS for p53 expression.
Conclusion: We demonstrated significantly different expression patterns of Her2/neu, PR and Ki67 in IDC versus IDC/DCIS. Since these molecular markers play important roles in carcinogenesis and tumor progression, IDC/DCIS could be an important subtype of mammary invasive ductal cancer. Differences in expression of the evaluated markers might suggest a higher malignant potential of invasive carcinomas alone. The lower expression of Her2/neu and Ki67 in IDC/DCIS could implicate a less malignant behavior compared to a differentiated IDC. Additionally, these results might suggest that DCIS might be a malignant preform and the interaction with neoplastic tissue could result in an aggressive type of invasive tumor.
Similar articles
-
Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25. Cell Biol Int. 2008. PMID: 18296077
-
Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.Ann Clin Lab Sci. 2007 Spring;37(2):127-34. Ann Clin Lab Sci. 2007. PMID: 17522367
-
Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases.Histopathology. 2005 Jan;46(1):43-9. doi: 10.1111/j.1365-2559.2005.02055.x. Histopathology. 2005. PMID: 15656885 Review.
-
Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.APMIS Suppl. 2003;(108):1-67. APMIS Suppl. 2003. PMID: 12874968 Review.
-
Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.J Surg Oncol. 2000 Jun;74(2):100-7. doi: 10.1002/1096-9098(200006)74:2<100::AID-JSO5>3.0.CO;2-O. J Surg Oncol. 2000. PMID: 10914818
Cited by
-
The role of MRI and clinicopathologic features in predicting the invasive component of biopsy-confirmed ductal carcinoma in situ.BMC Med Imaging. 2020 Aug 12;20(1):95. doi: 10.1186/s12880-020-00494-z. BMC Med Imaging. 2020. PMID: 32787871 Free PMC article.
-
Is there a difference in FDG PET findings of invasive ductal carcinoma of the breast with and without coexisting DCIS?Asia Ocean J Nucl Med Biol. 2020 Winter;8(1):27-35. doi: 10.22038/aojnmb.2019.41658.1284. Asia Ocean J Nucl Med Biol. 2020. PMID: 32064280 Free PMC article.
-
The prognostic significance of co-existence ductal carcinoma in situ in invasive ductal breast cancer: a large population-based study and a matched case-control analysis.Ann Transl Med. 2019 Sep;7(18):484. doi: 10.21037/atm.2019.08.16. Ann Transl Med. 2019. PMID: 31700920 Free PMC article.
-
The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.Br J Cancer. 2019 May;120(11):1075-1082. doi: 10.1038/s41416-019-0436-3. Epub 2019 May 8. Br J Cancer. 2019. PMID: 31065110 Free PMC article.
-
The Prognostic Impact of the Aryl Hydrocarbon Receptor (AhR) in Primary Breast Cancer Depends on the Lymph Node Status.Int J Mol Sci. 2019 Feb 26;20(5):1016. doi: 10.3390/ijms20051016. Int J Mol Sci. 2019. PMID: 30813617 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous